Increase in tacrolimus trough levels after steroid withdrawal

被引:95
作者
van Duijnhoven, EM
Boots, JMM
Christiaans, MHL
Stolk, LML
Undre, NA
van Hooff, JP
机构
[1] Univ Hosp Maastricht, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Clin Pharm, NL-6202 AZ Maastricht, Netherlands
[3] Fujisawa Germany, Munich, Germany
关键词
tacrolimus levels; steroid withdrawal; renal transplantation; pharmacokinetics;
D O I
10.1007/s00147-003-0615-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Although there are experimental reports of cytochrome P450 3A4 iso-enzyme (CYP3A4) induction by glucocorticoids, there are no clinical reports about an interaction between tacrolimus and steroids. Therefore, tacrolimus trough level and dose were compared after dose-normalization before and after withdrawal of prednisolone. After withdrawal of 5 mg prednisolone, the median tacrolimus dose-normalized level increased by 14% in the retrospective (n = 54), and by 11% in the prospective (n = 8) part of the study. After withdrawal of 10 mg, this increase was 33% (n = 30) and 36% (n = 14), respectively. An additional pharmacokinetic part of the study (n=8) revealed an 18% increase in AUC (P = 0.05) after withdrawal of 5 mg prednisolone, which is compatible with a reduced metabolism after steroid withdrawal. The significant increase in tacrolimus exposure after steroid withdrawal may on the one hand counteract the reduction in immunosuppression intended by steroid withdrawal, and, on the other hand, may result in an increase of serum creatinine which could be misinterpreted as rejection.
引用
收藏
页码:721 / 725
页数:5
相关论文
共 21 条
[1]  
Boots JMM, 2002, J AM SOC NEPHROL, V13, P221, DOI 10.1681/ASN.V131221
[2]   Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients [J].
Boots, JMM ;
van Duijnhoven, EM ;
Christiaans, MHL ;
Nieman, FHM ;
van Suylen, RJ ;
van Hooff, JP .
TRANSPLANT INTERNATIONAL, 2001, 14 (06) :370-383
[3]   Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression [J].
Chakrabarti, P ;
Wong, HY ;
Scantlebury, VP ;
Jordan, ML ;
Vivas, C ;
Ellis, D ;
Lombardozzi-Lane, S ;
Hakala, TR ;
Fung, JJ ;
Simmons, RL ;
Starzl, TE ;
Shapiro, R .
TRANSPLANTATION, 2000, 70 (05) :760-764
[4]   Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients [J].
Christiaans, M ;
van Duijnhoven, E ;
Beysens, T ;
Undre, N ;
Schäfer, A ;
van Hooff, J .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1271-1273
[5]  
HRICIK DE, 1994, J AM SOC NEPHROL S, V4, P10
[6]  
Johnson C, 2000, TRANSPLANTATION, V69, P834
[7]   P-glycoprotein and drug therapy in organ transplantation [J].
Lo, A ;
Burckart, GJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10) :995-1005
[8]   Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group [J].
Mayer, AD ;
Dmitrewski, J ;
Squifflet, JP ;
Besse, T ;
Grabensee, B ;
Klein, B ;
Eigler, FW ;
Heemann, U ;
Pichlmayr, R ;
Behrend, M ;
Vanrenterghem, Y ;
Donck, J ;
vanHooff, J ;
Christiaans, M ;
Morales, JM ;
Andres, A ;
Johnson, RWG ;
Short, C ;
Buchholz, B ;
Rehmert, N ;
Land, W ;
Schleibner, S ;
Forsythe, JLR ;
Talbot, D ;
Neumayer, HH ;
Hauser, I ;
Ericzon, BG ;
Brattstrom, C ;
Claesson, K ;
Muhlbacher, F ;
Pohanka, E .
TRANSPLANTATION, 1997, 64 (03) :436-443
[9]  
MOOCHHALA SM, 1991, TRANSPLANT P, V23, P2786
[10]  
OMAR G, 1993, TRANSPLANT P, V23, P690